In a nutshell This study wanted to find out which treatment was better before surgery for patients with HER2-positive breast cancer, trastuzumab emtansine (Kadcycla) plus pertuzumab (Perjeta), or a standard treatment. The study found that patients treated with trastuzumab emtansine plus pertuzumab (TEP) were more likely to have cancer...
Read MoreCurrent stage-Stage III Posts on Medivizor
Searching for patients with advanced breast cancer to trial a new treatment.
In a nutshell This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States. The...
Read MoreLooking for patients with locally advanced rectal cancer to test a chemotherapy treatment
In a nutshell This phase 2 trial is examining the effectiveness of FOLFOX chemotherapy to treat patients with rectal cancer, without surgery and radiation. The main outcome to be measured will be the tumor response to the treatment. This study is being conducted in New York, US. The details This year an estimated 44,180 people will be diagnosed with...
Read MoreSearching for patients with advanced triple negative breast cancer to trial a new treatment into the tumor
In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read MoreHow effective is postoperative radiotherapy after partial lung removal?
In a nutshell This study investigated if postoperative radiotherapy (PORT) is effective in non-small cell lung cancer (NSCLC) after pneumonectomy (PMT; lung surgery). They found that PORT improved survival and was well tolerated in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer....
Read MoreSearching for patients with colorectal cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with colorectal cancer (CRC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance). The details A treatment option for patients with...
Read MoreSearching for patients with lung cancer that cannot be operated on to test durvalumab after chemotherapy and radiation
In a nutshell This phase 2 trial will investigate the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer (NSCLC). The main outcomes will be the number of treatment-related adverse events (TRAEs) and progression-free survival (PFS). The details Non-small cell lung cancer (NSCLC)...
Read MoreLong-term outcomes for dabrafenib plus trametinib treatment for metastatic melanoma.
In a nutshell This study wanted to find out how well patients with advanced melanoma with mutations (abnormal genes) survive when treated with dabrafenib (Tafinlar) and trametinib (Mekinist) combination. The study found that long term, patients survived moderately well with this treatment. Some background Advanced melanoma can be hard to treat. In...
Read MoreEvaluating long-term outcomes of interferon treatment for advanced melanoma
In a nutshell This study examined the long-term outcomes of patients with melanoma who received surgery and high-dose interferon-α (HDI). This study found that HDI treatment resulted in a decreased chance of the cancer coming back after 17 years. Some background Surgery followed by anti-cancer therapy has remained the standard of care...
Read MoreEvaluating osimertinib for elderly patients over age 80 with advanced NSCLC
In a nutshell This study evaluated the effectiveness of osimertinib (Tagrisso) in patients over age 80 with advanced small cell lung cancer (NSCLC). This study found that these elderly patients had similar outcomes to patients in clinical trials. Some background NSCLC is the most common type of lung cancer. One common treatment is...
Read MoreEvaluating quality of life for survivors of melanoma after immunotherapy treatment
In a nutshell This study evaluated the quality of life for survivors of melanoma who received immunotherapy. This study found that melanoma survivors had a significantly lower quality of life compared to the general population. Some background Immune checkpoint inhibitors are a new class of anti-cancer drugs that take advantage of the...
Read MoreLooking patients with advanced cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read More
